Human hepatitis B vaccine from recombinant yeast
The worldwide importance of human hepatitis B virus infection and the toll it takes in chronic liver disease, cirrhosis and hepatocarcinoma, make it imperative that a vaccine be developed for worldwide application 1 . Human hepatitis B vaccines 2–6 are presently prepared using hepatitis B surface an...
Gespeichert in:
| Veröffentlicht in: | Nature (London) 1984-01, Vol.307 (5947), p.178-180 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 180 |
|---|---|
| container_issue | 5947 |
| container_start_page | 178 |
| container_title | Nature (London) |
| container_volume | 307 |
| creator | McAleer, William J. Buynak, Eugene B. Maigetter, Robert Z. Wampler, D. Eugene Miller, William J. Hilleman, Maurice R. |
| description | The worldwide importance of human hepatitis B virus infection and the toll it takes in chronic liver disease, cirrhosis and hepatocarcinoma, make it imperative that a vaccine be developed for worldwide application
1
. Human hepatitis B vaccines
2–6
are presently prepared using hepatitis B surface antigen (HBsAg) that is purified from the plasma of human carriers of hepatitis B virus infection. The preparation of hepatitis B vaccine from a human source is restricted by the available supply of infected human plasma and by the need to apply stringent processes that purify the antigen and render it free of infectious hepatitis B virus and other possible living agents that might be present in the plasma. Joint efforts between our laboratories and those of Drs W. Rutter and B. Hall led to the preparation of vectors carrying the DNA sequence
7,8
for HBsAg and antigen expression in the yeast
Saccharomyces cerevisiae
9
. Here we describe the development of hepatitis B vaccine of yeast cell origin. HBsAg of subtype adw was produced in recombinant yeast cell culture, and the purified antigen in alum formulation stimulated production of antibody in mice, grivet monkeys and chimpanzees. Vaccinated chimpanzees were totally protected when challenged intravenously with either homologous or heterologous subtype adr and ayw virus of human serum source. This is the first example of a vaccine produced from recombinant cells which is effective against a human viral infection. |
| doi_str_mv | 10.1038/307178a0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80922324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14104645</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-67d075b016d5c9a7841a0115cb35b3defe0d522ea60f080a0b9bbc48bacc0ec93</originalsourceid><addsrcrecordid>eNqNkE1LxDAURYMo4zgK_gGhCxFdVF8-mqRLHdQRBtzouiRpqh3adExaYf69kamzcaGrt7iHex8HoVMM1xiovKEgsJAK9tAUM8FTxqXYR1MAIlOQlB-ioxBWAJBhwSZowimWmLApgsXQKpe827Xq674OyV3yqYypnU0q37WJt6Zrde2U65ONVaE_RgeVaoI9Ge8MvT7cv8wX6fL58Wl-u0wNE7RPuShBZBowLzOTKyEZVoBxZjTNNC1tZaHMCLGKQwUSFOhca8OkjuNgTU5n6GLbu_bdx2BDX7R1MLZplLPdEAoJOSGUsD9BzAgGyPE_QAyMsyyCl1vQ-C4Eb6ti7etW-U2BofjWXfzojujZ2Dno1pY7cPQb8_MxV8GopvLKmTrssJzH16KvGbraYiEm7s36YtUN3kW_vye_AMSSkgA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14104645</pqid></control><display><type>article</type><title>Human hepatitis B vaccine from recombinant yeast</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature</source><creator>McAleer, William J. ; Buynak, Eugene B. ; Maigetter, Robert Z. ; Wampler, D. Eugene ; Miller, William J. ; Hilleman, Maurice R.</creator><creatorcontrib>McAleer, William J. ; Buynak, Eugene B. ; Maigetter, Robert Z. ; Wampler, D. Eugene ; Miller, William J. ; Hilleman, Maurice R.</creatorcontrib><description>The worldwide importance of human hepatitis B virus infection and the toll it takes in chronic liver disease, cirrhosis and hepatocarcinoma, make it imperative that a vaccine be developed for worldwide application
1
. Human hepatitis B vaccines
2–6
are presently prepared using hepatitis B surface antigen (HBsAg) that is purified from the plasma of human carriers of hepatitis B virus infection. The preparation of hepatitis B vaccine from a human source is restricted by the available supply of infected human plasma and by the need to apply stringent processes that purify the antigen and render it free of infectious hepatitis B virus and other possible living agents that might be present in the plasma. Joint efforts between our laboratories and those of Drs W. Rutter and B. Hall led to the preparation of vectors carrying the DNA sequence
7,8
for HBsAg and antigen expression in the yeast
Saccharomyces cerevisiae
9
. Here we describe the development of hepatitis B vaccine of yeast cell origin. HBsAg of subtype adw was produced in recombinant yeast cell culture, and the purified antigen in alum formulation stimulated production of antibody in mice, grivet monkeys and chimpanzees. Vaccinated chimpanzees were totally protected when challenged intravenously with either homologous or heterologous subtype adr and ayw virus of human serum source. This is the first example of a vaccine produced from recombinant cells which is effective against a human viral infection.</description><identifier>ISSN: 0028-0836</identifier><identifier>EISSN: 1476-4687</identifier><identifier>DOI: 10.1038/307178a0</identifier><identifier>PMID: 6318124</identifier><identifier>CODEN: NATUAS</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Animals ; antibody response ; Biological and medical sciences ; DNA ; DNA, Recombinant ; Fundamental and applied biological sciences. Psychology ; Genetic Vectors ; Glycoproteins - immunology ; Hepatitis B - immunology ; hepatitis B surface antigen ; Hepatitis B Surface Antigens - genetics ; Humanities and Social Sciences ; Humans ; Immunization ; letter ; Microbiology ; multidisciplinary ; Pan troglodytes ; Primates ; Saccharomyces cerevisiae ; Saccharomyces cerevisiae - genetics ; Science ; Science (multidisciplinary) ; transfection ; vaccination ; vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Viral Vaccines - immunology ; Virology</subject><ispartof>Nature (London), 1984-01, Vol.307 (5947), p.178-180</ispartof><rights>Springer Nature Limited 1984</rights><rights>1984 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-67d075b016d5c9a7841a0115cb35b3defe0d522ea60f080a0b9bbc48bacc0ec93</citedby><cites>FETCH-LOGICAL-c473t-67d075b016d5c9a7841a0115cb35b3defe0d522ea60f080a0b9bbc48bacc0ec93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/307178a0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/307178a0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9610047$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6318124$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McAleer, William J.</creatorcontrib><creatorcontrib>Buynak, Eugene B.</creatorcontrib><creatorcontrib>Maigetter, Robert Z.</creatorcontrib><creatorcontrib>Wampler, D. Eugene</creatorcontrib><creatorcontrib>Miller, William J.</creatorcontrib><creatorcontrib>Hilleman, Maurice R.</creatorcontrib><title>Human hepatitis B vaccine from recombinant yeast</title><title>Nature (London)</title><addtitle>Nature</addtitle><addtitle>Nature</addtitle><description>The worldwide importance of human hepatitis B virus infection and the toll it takes in chronic liver disease, cirrhosis and hepatocarcinoma, make it imperative that a vaccine be developed for worldwide application
1
. Human hepatitis B vaccines
2–6
are presently prepared using hepatitis B surface antigen (HBsAg) that is purified from the plasma of human carriers of hepatitis B virus infection. The preparation of hepatitis B vaccine from a human source is restricted by the available supply of infected human plasma and by the need to apply stringent processes that purify the antigen and render it free of infectious hepatitis B virus and other possible living agents that might be present in the plasma. Joint efforts between our laboratories and those of Drs W. Rutter and B. Hall led to the preparation of vectors carrying the DNA sequence
7,8
for HBsAg and antigen expression in the yeast
Saccharomyces cerevisiae
9
. Here we describe the development of hepatitis B vaccine of yeast cell origin. HBsAg of subtype adw was produced in recombinant yeast cell culture, and the purified antigen in alum formulation stimulated production of antibody in mice, grivet monkeys and chimpanzees. Vaccinated chimpanzees were totally protected when challenged intravenously with either homologous or heterologous subtype adr and ayw virus of human serum source. This is the first example of a vaccine produced from recombinant cells which is effective against a human viral infection.</description><subject>Animals</subject><subject>antibody response</subject><subject>Biological and medical sciences</subject><subject>DNA</subject><subject>DNA, Recombinant</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genetic Vectors</subject><subject>Glycoproteins - immunology</subject><subject>Hepatitis B - immunology</subject><subject>hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens - genetics</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Immunization</subject><subject>letter</subject><subject>Microbiology</subject><subject>multidisciplinary</subject><subject>Pan troglodytes</subject><subject>Primates</subject><subject>Saccharomyces cerevisiae</subject><subject>Saccharomyces cerevisiae - genetics</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>transfection</subject><subject>vaccination</subject><subject>vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Viral Vaccines - immunology</subject><subject>Virology</subject><issn>0028-0836</issn><issn>1476-4687</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1LxDAURYMo4zgK_gGhCxFdVF8-mqRLHdQRBtzouiRpqh3adExaYf69kamzcaGrt7iHex8HoVMM1xiovKEgsJAK9tAUM8FTxqXYR1MAIlOQlB-ioxBWAJBhwSZowimWmLApgsXQKpe827Xq674OyV3yqYypnU0q37WJt6Zrde2U65ONVaE_RgeVaoI9Ge8MvT7cv8wX6fL58Wl-u0wNE7RPuShBZBowLzOTKyEZVoBxZjTNNC1tZaHMCLGKQwUSFOhca8OkjuNgTU5n6GLbu_bdx2BDX7R1MLZplLPdEAoJOSGUsD9BzAgGyPE_QAyMsyyCl1vQ-C4Eb6ti7etW-U2BofjWXfzojujZ2Dno1pY7cPQb8_MxV8GopvLKmTrssJzH16KvGbraYiEm7s36YtUN3kW_vye_AMSSkgA</recordid><startdate>19840101</startdate><enddate>19840101</enddate><creator>McAleer, William J.</creator><creator>Buynak, Eugene B.</creator><creator>Maigetter, Robert Z.</creator><creator>Wampler, D. Eugene</creator><creator>Miller, William J.</creator><creator>Hilleman, Maurice R.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7T7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>19840101</creationdate><title>Human hepatitis B vaccine from recombinant yeast</title><author>McAleer, William J. ; Buynak, Eugene B. ; Maigetter, Robert Z. ; Wampler, D. Eugene ; Miller, William J. ; Hilleman, Maurice R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-67d075b016d5c9a7841a0115cb35b3defe0d522ea60f080a0b9bbc48bacc0ec93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Animals</topic><topic>antibody response</topic><topic>Biological and medical sciences</topic><topic>DNA</topic><topic>DNA, Recombinant</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genetic Vectors</topic><topic>Glycoproteins - immunology</topic><topic>Hepatitis B - immunology</topic><topic>hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens - genetics</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Immunization</topic><topic>letter</topic><topic>Microbiology</topic><topic>multidisciplinary</topic><topic>Pan troglodytes</topic><topic>Primates</topic><topic>Saccharomyces cerevisiae</topic><topic>Saccharomyces cerevisiae - genetics</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>transfection</topic><topic>vaccination</topic><topic>vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Viral Vaccines - immunology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McAleer, William J.</creatorcontrib><creatorcontrib>Buynak, Eugene B.</creatorcontrib><creatorcontrib>Maigetter, Robert Z.</creatorcontrib><creatorcontrib>Wampler, D. Eugene</creatorcontrib><creatorcontrib>Miller, William J.</creatorcontrib><creatorcontrib>Hilleman, Maurice R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Nature (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McAleer, William J.</au><au>Buynak, Eugene B.</au><au>Maigetter, Robert Z.</au><au>Wampler, D. Eugene</au><au>Miller, William J.</au><au>Hilleman, Maurice R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human hepatitis B vaccine from recombinant yeast</atitle><jtitle>Nature (London)</jtitle><stitle>Nature</stitle><addtitle>Nature</addtitle><date>1984-01-01</date><risdate>1984</risdate><volume>307</volume><issue>5947</issue><spage>178</spage><epage>180</epage><pages>178-180</pages><issn>0028-0836</issn><eissn>1476-4687</eissn><coden>NATUAS</coden><abstract>The worldwide importance of human hepatitis B virus infection and the toll it takes in chronic liver disease, cirrhosis and hepatocarcinoma, make it imperative that a vaccine be developed for worldwide application
1
. Human hepatitis B vaccines
2–6
are presently prepared using hepatitis B surface antigen (HBsAg) that is purified from the plasma of human carriers of hepatitis B virus infection. The preparation of hepatitis B vaccine from a human source is restricted by the available supply of infected human plasma and by the need to apply stringent processes that purify the antigen and render it free of infectious hepatitis B virus and other possible living agents that might be present in the plasma. Joint efforts between our laboratories and those of Drs W. Rutter and B. Hall led to the preparation of vectors carrying the DNA sequence
7,8
for HBsAg and antigen expression in the yeast
Saccharomyces cerevisiae
9
. Here we describe the development of hepatitis B vaccine of yeast cell origin. HBsAg of subtype adw was produced in recombinant yeast cell culture, and the purified antigen in alum formulation stimulated production of antibody in mice, grivet monkeys and chimpanzees. Vaccinated chimpanzees were totally protected when challenged intravenously with either homologous or heterologous subtype adr and ayw virus of human serum source. This is the first example of a vaccine produced from recombinant cells which is effective against a human viral infection.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>6318124</pmid><doi>10.1038/307178a0</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-0836 |
| ispartof | Nature (London), 1984-01, Vol.307 (5947), p.178-180 |
| issn | 0028-0836 1476-4687 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80922324 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature |
| subjects | Animals antibody response Biological and medical sciences DNA DNA, Recombinant Fundamental and applied biological sciences. Psychology Genetic Vectors Glycoproteins - immunology Hepatitis B - immunology hepatitis B surface antigen Hepatitis B Surface Antigens - genetics Humanities and Social Sciences Humans Immunization letter Microbiology multidisciplinary Pan troglodytes Primates Saccharomyces cerevisiae Saccharomyces cerevisiae - genetics Science Science (multidisciplinary) transfection vaccination vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Viral Vaccines - immunology Virology |
| title | Human hepatitis B vaccine from recombinant yeast |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A17%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20hepatitis%20B%20vaccine%20from%20recombinant%20yeast&rft.jtitle=Nature%20(London)&rft.au=McAleer,%20William%20J.&rft.date=1984-01-01&rft.volume=307&rft.issue=5947&rft.spage=178&rft.epage=180&rft.pages=178-180&rft.issn=0028-0836&rft.eissn=1476-4687&rft.coden=NATUAS&rft_id=info:doi/10.1038/307178a0&rft_dat=%3Cproquest_cross%3E14104645%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14104645&rft_id=info:pmid/6318124&rfr_iscdi=true |